Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Cancer
    August 2026
  1. FREEDLAND SJ, Gao W, Touya M, Yang H, et al
    How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data.
    Cancer. 2026;132:e70494.
    >> Share

  2. LAWRENCE L
    PSA monitoring alone proves inadequate for detecting prostate cancer progression.
    Cancer. 2026;132:e70512.
    >> Share

  3. LAWRENCE L
    Estradiol patches noninferior to LHRH agonists in locally advanced prostate cancer.
    Cancer. 2026;132:e70511.
    >> Share

    July 2026
  4. MCKAY RR, Xie W, Ajmera A, Araneta A, et al
    Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
    Cancer. 2026;132:e70496.
    >> Share

  5. CHENG Y, Huang H, Wang M, Zhu L, et al
    Magnetic resonance imaging-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial.
    Cancer. 2026;132:e70493.
    >> Share

    June 2026
  6. PIWARSKI SA, Howard LE, Paul MA, Bachelder N, et al
    Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.
    Cancer. 2026;132:e70371.
    >> Share

  7. ZENG J, Chen MH, Wu J, Xie W, et al
    Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.
    Cancer. 2026;132:e70469.
    >> Share

  8. LAWRENCE L
    Study adds new evidence on use of salvage focal therapy for radio-recurrent prostate cancer.
    Cancer. 2026;132:e70404.
    >> Share

  9. MARULANDA-CORZO V, Coraci S, Kakkar P, Okobi TJ, et al
    Top advances of the year: Radiopharmaceutical therapy for prostate cancer.
    Cancer. 2026;132:e70470.
    >> Share

    April 2026
  10. GERKE MB, Marra A, Liu Y, Bedmutha A, et al
    Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.
    Cancer. 2026;132:e70410.
    >> Share

  11. VAN TUIJL LA, Pan KY, Basten M, Vermeulen R, et al
    Psychosocial factors and the risk of cancer: An individual-participant data meta-analysis.
    Cancer. 2026;132:e70271.
    >> Share

    March 2026
  12. WANG TF, Clarke A, Rath M, Yoo S, et al
    Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents.
    Cancer. 2026;132:e70266.
    >> Share

  13. BORGERT B, Kay H, Basak RS, Usinger D, et al
    Impact of smoking on health-related quality-of-life outcomes in prostate cancer survivors.
    Cancer. 2026;132:e70336.
    >> Share

  14. GANN PH, Stackhouse N, Gastala N, Ma W, et al
    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population.
    Cancer. 2026;132:e70340.
    >> Share

    February 2026
  15. LANE BR, Lewicki P, Noyes SL, Labardee C, et al
    Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.
    Cancer. 2026;132:e70291.
    >> Share

  16. MCKAY RR, Maughan BL, Morgans AK, Shore ND, et al
    Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.
    Cancer. 2026;132:e70304.
    >> Share

  17. VENKATESWARAN S, Mantena RV, Willmann J, Zhang YH, et al
    Not all progression is equal.
    Cancer. 2026;132:e70311.
    >> Share

  18. MONTGOMERY B, Lynch JA, Brown J, Maxwell KN, et al
    Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.
    Cancer. 2026;132:e70283.
    >> Share

    January 2026
  19. DUDIPALA H, Nazari SS, Werneck da Cunha I, Coligado N, et al
    Molecular alteration profiles characterize intraductal carcinoma of the prostate.
    Cancer. 2026;132:e70238.
    >> Share

  20. GEBRAEL G, Agarwal N, Morgans AK, Vince R Jr, et al
    Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.
    Cancer. 2026;132:e70236.
    >> Share

    December 2025
  21. GRUTMAN AJ, Pavlovich CP
    The One Big Beautiful Bill Act and the future of prostate cancer care.
    Cancer. 2025;131:e70186.
    >> Share

  22. KUMAR A, LaBella DA, Snider MC, Acklin-Wehnert SM, et al
    Prognostic significance of magnetic resonance imaging-detected extraprostatic extension in localized prostate cancer.
    Cancer. 2025;131:e70191.
    >> Share

    November 2025
  23. GOGEBAKAN KC, Elsisi Z, Montano-Campos F, Owens L, et al
    Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
    Cancer. 2025;131:e70131.
    >> Share

  24. HUANG MM, Driscoll CB, Handa N, Wahba BM, et al
    Cost-effectiveness of office-based, magnetic resonance imaging-guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial.
    Cancer. 2025;131:e70118.
    >> Share

  25. LIU MA, Raghunathan R, Runcie K, Wooster M, et al
    Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors.
    Cancer. 2025;131:e70163.
    >> Share

    October 2025
  26. ROVIELLO G, Catalano M, Antonuzzo L
    From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
    Cancer. 2025;131:e70117.
    >> Share

  27. TSUNG I, Reichert ZR, Ramalingam SS
    Reply to "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer".
    Cancer. 2025;131:e70119.
    >> Share


  28. Erratum to "Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative".
    Cancer. 2025;131:e70105.
    >> Share

    September 2025
  29. NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al
    Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
    Cancer. 2025;131:e70070.
    >> Share

  30. NIERENGARTEN MB
    Outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated radiation therapy for localized prostate cancer.
    Cancer. 2025;131:e70013.
    >> Share

  31. NIERENGARTEN MB
    A persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis.
    Cancer. 2025;131:e70012.
    >> Share

    August 2025
  32. TSUNG I, Yentz SE, Reichert ZR
    Controversies in metastatic hormone-sensitive prostate cancer.
    Cancer. 2025;131:e70030.
    >> Share

  33. NORIEGA ESQUIVES BS, Manoharan A, Penedo FJ, Dee EC, et al
    Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos.
    Cancer. 2025;131:e70029.
    >> Share

  34. SANDERS J, Levell C, Brand LJ, Dahut WL, et al
    Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative.
    Cancer. 2025;131:e70010.
    >> Share

  35. SAEED F, Berchuck JE, Bilen MA, Gandhi JS, et al
    Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
    Cancer. 2025;131:e70037.
    >> Share

  36. FALAGARIO UG, Pellegrino F, Abbadi A, Bjornebo L, et al
    Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.
    Cancer. 2025;131:e70045.
    >> Share

  37. GREEN-LOTT AY, Wadhwa A, Bailey AV, Kwan L, et al
    Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration.
    Cancer. 2025;131:e70007.
    >> Share

  38. NIERENGARTEN MB
    Superior prostate cancer detection with LATP versus TRUS.
    Cancer. 2025;131:e35958.
    >> Share

    July 2025
  39. GRANT RS, Kakani P, Movva P, Daskivich TJ, et al
    Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.
    Cancer. 2025;131:e35968.
    >> Share

    June 2025
  40. NIERENGARTEN MB
    Acute toxicity of prostate cancer radiotherapy associated with late toxicity: Acute toxicity following prostate cancer radiotherapy was statistically and significantly associated with late toxicity in patient-reported quality-of-life metrics.
    Cancer. 2025;131:e35886.
    >> Share

  41. GINSBURG KB, Sessine MS, Bock CH, Goodman M, et al
    Factors associated with switching from active surveillance to treatment in men with low-risk prostate cancer: A population-based study.
    Cancer. 2025;131:e35909.
    >> Share

    May 2025
  42. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    >> Share

    April 2025
  43. LAWRENCE WR, Freedman ND, McGee-Avila JK, Hong HG, et al
    Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival.
    Cancer. 2025;131:e35850.
    >> Share

  44. FUKUOKAYA W, Mori K, Yanagisawa T, Urabe F, et al
    Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.
    Cancer. 2025;131:e35819.
    >> Share

    March 2025
  45. SEBASTIAN NT, Patil D, Patel PR, Jani AB, et al
    Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
    Cancer. 2025;131:e35795.
    >> Share

  46. NIERENGARTEN MB
    Higher rates of long-term complications after prostate cancer treatment.
    Cancer. 2025;131:e35761.
    >> Share

  47. NIERENGARTEN MB
    Reduced long-term side effects with MRI-guided radiotherapy in prostate cancer.
    Cancer. 2025;131:e35762.
    >> Share

    February 2025
  48. NIERENGARTEN MB
    Healthy diet may reduce the risk of low-grade prostate cancer progressing to a higher grade.
    Cancer. 2025;131:e35740.
    >> Share

    January 2025
  49. CASTANEDA P, Kuhlmann PK, Ithisuphalap J, Howard LE, et al
    Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
    Cancer. 2025;131:e35684.
    >> Share

  50. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    >> Share

    December 2024
  51. MUKAND NH, Chirikova E, Lichtensztajn D, Negoita S, et al
    Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.
    Cancer. 2024;130:4298-4305.
    >> Share

  52. SAYAN M, Chen MH, Wu J, Leeman JE, et al
    Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial.
    Cancer. 2024 Dec 4. doi: 10.1002/cncr.35674.
    >> Share

  53. BRYCE AH, Agarwal N, Beltran H, Hussain MH, et al
    Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
    Cancer. 2024 Dec 1. doi: 10.1002/cncr.35612.
    >> Share

    November 2024
  54. SRIVASTAVA A, Liu X, Maganty A, Kaufman SR, et al
    Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.
    Cancer. 2024 Nov 5. doi: 10.1002/cncr.35633.
    >> Share

  55. SOERENSEN SJC, Lim DS, Montez-Rath ME, Chertow GM, et al
    Pesticides and prostate cancer incidence and mortality: An environment-wide association study.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35572.
    >> Share

    October 2024
  56. NIERENGARTEN MB
    Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer.
    Cancer. 2024;130:3399.
    >> Share

  57. MOUSA A, Nguyen DD, Lalani AK, Satkunasivam R, et al
    Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
    Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606.
    >> Share

  58. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality.
    Cancer. 2024 Oct 8. doi: 10.1002/cncr.35563.
    >> Share

    September 2024
  59. ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al
    Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
    Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568.
    >> Share

  60. KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al
    Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498.
    >> Share


  61. Addition of apalutamide to ADT after radical prostatectomy offers encouraging results.
    Cancer. 2024;130:2896.
    >> Share

  62. NIERENGARTEN MB
    Optimal timing of radiotherapy after radical prostatectomy points to salvage radiotherapy for PSA failure.
    Cancer. 2024;130:2895.
    >> Share

    August 2024
  63. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    >> Share

    July 2024
  64. MORGANS AK
    Optimizing assessments of quality of life in contemporary prostate cancer clinical trials.
    Cancer. 2024 Jul 27. doi: 10.1002/cncr.35485.
    >> Share

  65. LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al
    Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472.
    >> Share

  66. MEAGHER M, Morgan K, Deshler L, Riviere P, et al
    Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469.
    >> Share

  67. SANYAL C, Ragavan MV
    Beyond the PSA: The hidden costs of screening in prostate cancer.
    Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474.
    >> Share

  68. NIERENGARTEN MB
    Novel hormone is safe and effective in men receiving radiotherapy for prostate cancer.
    Cancer. 2024;130:2408.
    >> Share

  69. SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al
    Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
    Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392.
    >> Share

  70. GONG J, Janes JL, Trustram Eve C, Stock S, et al
    Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
    Cancer. 2024 Jul 1. doi: 10.1002/cncr.35466.
    >> Share

    June 2024
  71. MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al
    Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438.
    >> Share

  72. BASARIA S, Taplin ME, McDonnell M, Simonson DC, et al
    Insulin resistance during androgen deprivation therapy in men with prostate cancer.
    Cancer. 2024 Jun 16. doi: 10.1002/cncr.35443.
    >> Share

  73. PAGADALA MS, Lui A, Lynch J, Karunamuni R, et al
    Healthy lifestyle and prostate cancer risk in the Million Veteran Program.
    Cancer. 2024 Jun 12. doi: 10.1002/cncr.35434.
    >> Share

  74. LABBAN M, Stone BV, Steele GL, Salinas KE, et al
    A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366.
    >> Share

    May 2024
  75. TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al
    Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
    >> Share

    April 2024
  76. BENADADA F, Saad F, Delouya G, Taussky D, et al
    Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries.
    Cancer. 2024;130:1019-1024.
    >> Share

    March 2024
  77. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
    A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
    >> Share

  78. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
    High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
    Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
    >> Share

  79. LIM FAT G, Alibhai S
    Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
    >> Share

  80. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    >> Share

    February 2024
  81. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    >> Share

  82. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    >> Share

  83. WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al
    The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241.
    >> Share

  84. LOEB S, Hua Q, Bauer SR, Kenfield SA, et al
    Plant-based diet associated with better quality of life in prostate cancer survivors.
    Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172.
    >> Share

  85. HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al
    Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221.
    >> Share

  86. DORFF TB, Bryce AH
    Challenges in clinical trials for high-risk but curable prostate cancer.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245.
    >> Share

  87. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    >> Share

    January 2024
  88. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    >> Share

  89. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    >> Share

  90. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    >> Share

  91. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    >> Share

    December 2023
  92. FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al
    Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168.
    >> Share


  93. FDA approves new combined treatment for advanced prostate cancer.
    Cancer. 2023;129:3841-3842.
    >> Share

  94. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Reply to "Contextualizing racial associations in prostate cancer to expose structural causes".
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167.
    >> Share

  95. ROLLIN FG, Olsen E, George M
    Contextualizing racial associations in prostate cancer to expose structural causes.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157.
    >> Share

  96. GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al
    The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Cancer. 2023;129:3790-3796.
    >> Share

    November 2023
  97. YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al
    Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
    Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133.
    >> Share

  98. NIERENGARTEN MB
    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.
    >> Share

  99. BRAWLEY OW, Ramalingam R
    The enigma of race and prostate cancer.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032.
    >> Share

  100. LEE KM, Bryant AK, Lynch JA, Robison B, et al
    Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979.
    >> Share

    October 2023
  101. NIERENGARTEN MB
    Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities.
    Cancer. 2023;129:3192.
    >> Share

  102. LEEMAN JE, Shin KY, Chen YH, Mak RH, et al
    Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Cancer. 2023;129:3044-3052.
    >> Share

    September 2023
  103. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Racial differences in serum chemokines in prostate cancer patients.
    Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012.
    >> Share

    August 2023
  104. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
    Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
    Cancer. 2023;129:2522-2531.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016